ライフサイエンスコーパス: biologics

1 vel therapeutics (183 pharmaceuticals and 39 biologics).

2 e total psoriasis sample, of whom 37.2% used biologics.

3 r prescribing of generic drugs and follow-on biologics.

4 gical approaches, surgical determinants, and biologics.

5 etween IBD patients treated with and without biologics.

6 ssays to predict cytokine storm responses to biologics.

7 ill unmet needs in improving the delivery of biologics.

8 ue would allow for rapid generation of novel biologics.

9 l small molecule chemotherapeutic agents and biologics.

10 o pharmaceutical manufacturers for drugs and biologics.

11 vation of competent cardiogenic regenerative biologics.

12 HCP contamination in recombinantly produced biologics.

13 ul tool for drug discovery and for design of biologics.

14 including 60 using methotrexate and 15 using biologics.

15 event these infections in patients receiving biologics.

16 an important group of plant defense peptide biologics.

17 oing trials testing the efficacy of anti-IFN biologics.

18 s beyond existing oral DMARDs and parenteral biologics.

19 ccines and the intestinal absorption of oral biologics.

20 conduct a continuous size-based analysis of biologics.

21 imental origins to the original subjects and biologics.

22 delivery vehicles for oral administration of biologics.

23 ediated diseases, including those exposed to biologics.

24 mall molecules and systemically administered biologics.

25 potential with efficacy similar to anti-TNF biologics.

26 in the IRF-1 tumor suppressor pathway using biologics.

27 should be avoided in combination with other biologics.

28 on needs to be exercised when evaluating new biologics.

29 A who are resitant to conventional DMARDs or biologics.

30 for first-in-man phase-I clinical trials of biologics.

31 ith disease-modifying antirheumatic drugs or biologics.

32 surface display of proteins and delivery of biologics.

33 icient methods for detection of the agent in biologics.

34 ome a new strategy for PEGylation of protein biologics.

35 % CI 0.4-2.5) for those not receiving MTX or biologics.

36 ecently completed for a growing array of new biologics.

37 me short-term intra-articular effects of new biologics.

38 capabilities compared to small molecules and biologics.

39 strategy is compatible with a wide array of biologics.

40 rsification studies with small molecules and biologics.

41 , and no previous use of immunomodulators or biologics.

42 ically modified bacteria for the delivery of biologics.

43 vention trials with specific agents, such as biologics.

44 r new strategies to generate next-generation biologics.

45 n underlying the efficacy of these and other biologics.

46 ely to respond to inhaled corticosteroids or biologics.

47 ts may also benefit from anti-IL-17-targeted biologics.

48 ties suited to the design of multifunctional biologics.

49 cells are the main workhorses for producing biologics.

50 de Onderzoekacties of KU Leuven; and Janssen Biologics.

51 Continuous production of biologics, a growing trend in the biopharmaceutical indu

52 Diagnostics), AS03 and AS04 (GlaxoSmithKline Biologics), AF03 (Sanofi), and liposomes (Crucell).

53 hin lipid-based carriers protects the labile biologics against enzymatic degradation, hence reducing

54 ry data suggest, in combination with certain biologics agents.

55 f stem cell-derived cardiomyocytes and other biologics all necessitate high-throughput (HT), cellular

56 mportant consideration in the development of biologics and a critical aspect of regulatory filings.

57 y stage of the development and production of biologics and bio-therapeutic formulations.

58 The growing importance of biologics and biosimilars as therapeutic and diagnostic

59 nfliximab (IFX) with patients not exposed to biologics and calculated standardized incidence ratios (

60 stem cell transplantation, immunosuppressive biologics and drugs, and supportive care.

61 ntial alternative method for the delivery of biologics and engineering MSCs.

62 Two trends related to drugs/biologics and generic drugs/biosimilars underlie this ov

63 itizes ovarian tumors to platinum agents and biologics and has shown clinical promise against ovarian

64 soriasis and its treatments, with a focus on biologics and identification of factors associated with

65 at age 60 years or older with a lower use of biologics and immunomodulators but higher absolute risk

66 adult-onset IBD, elderly patients used fewer biologics and immunomodulators but more systemic cortico

67 Adverse events of potent treatment with biologics and immunomodulators have been recognized.

68 e treatments, though a consensus agreed that biologics and intravenous immunoglobulin were considered

69 rugs offer future alternatives to the use of biologics and less costly long-term disease management.

70 tient characteristics were found between the biologics and nonmethotrexate/nonbiologics cohorts (eg,

71 Clinical trials with combinations of biologics and other disease-modifying antirheumatic drug

72 A new crop of biologics and pharmaceuticals with increased molecular s

73 mparative efficacy, cardiovascular safety of biologics and potential anti-TNF therapy discontinuation

74 of new therapeutic options with a number of biologics and small molecules targeting potential key me

75 The development of effective biologics and small-molecule kinase inhibitors in the pa

76 h incorporate various combinations of drugs, biologics and targeting ligands within a single carrier

77 gnaling and growth using small molecules and biologics and to facilitate the discovery of drug-respon

78 tempt to give a bird's-eye view of the major biologics and to highlight insights and implications der

79 The association between use of biologics and tuberculosis is well known.

80 libraries as a robust method to discover new biologics and uncover membrane-to-nucleus signaling path

81 e framework for development of effective CMV biologics and vaccine design strategies.

82 is an important first step toward design of biologics and vaccines.

83 ntroduction of new efficacious agents, both "biologics" and traditional small molecules.

84 he most commonly investigated modality, GTR, biologics, and combination therapies have also been show

85 er agents including small molecule drugs and biologics, and discuss the challenges and future perspec

86 linical trials for cytomegalovirus vaccines, biologics, and drugs.

87 The risk of melanoma is increased by use of biologics, and the risk of NMSC is increased by use of t

88 Despite the clinical success of biologics (antibodies, soluble receptors) for treating T

89 Furthermore, the biologics appear to stimulate inflammatory mediators, an

90 rier, bone replacement graft with or without biologics) appears to offer an advantage over monotherap

91 Drugs and biologics approved by the FDA that mention TPPs are asso

92 esearch and is being used to produce several biologics approved for use in human or veterinary medici

93 In addition, existing biologics approved for use in other diseases, such as ri

94 study to determine which patients receiving biologics are at greatest risk.

95 Several biologics are currently available that target proinflamm

96 hat are capable of rapid characterization of biologics are essential to ensure the desired product ch

97 We cannot predict which biologics are going to be effective in humans, as many o

98 Biologics are made of protein components, and thus can b

99 Immunomodulators and biologics are now the preferred treatment options for Cr

100 Moreover, effects of other biologics are now understood to in part be mediated by e

101 mmatory drugs, intra-articular steroids, and biologics are reviewed, with generally nondifferentiable

102 and triplets (FOLFOXIRI) in combination with biologics are standard regimens, and efforts are ongoing

103 Although most of these biologics are tested and approved for one or a few indic

104 As new therapeutics (e.g., biologics) are being developed, there is an accompanying

105 Biologic agents (also termed biologicals or biologics) are therapeutics that are synthesized by livi

106 pharmaceutical products, or brand drugs and biologics, are at levels that some assessments consider

107 Biologically derived therapeutics, or biologics, are the most rapidly growing segment of the p

108 critical for the manufacture of high-quality biologics as it enables continuous, real-time and on-lin

109 e with portable or distributed production of biologics, as they typically require the development of

110 The data concerning biologics' associated toxicity in patients with inflamma

111 Among 633 patients exposed to biologics at the time of vaccination or within the subse

112 Co-administration of biologics blocking PD-1 and promoting OX40 signaling ind

113 e evidence regarding the potential safety of biologics both alone and in conjunction with nonbiologic

114 In the group of AS patients not treated with biologics, both M-CSF and MMP-3 correlated with the Bath

115 Most patients pay less than $20/week for biologics, but a small number have high OOP expenses, as

116 acy of immunostimulatory small molecules and biologics by altering their co-localization, biodistribu

117 Immune responses against non-vaccine biologics can affect their efficacy and safety, resultin

118 tent beyond which the viability of preserved biologics can be greatly compromised.

119 advancement and a definitive system by which biologics can be tested and paves the way for personaliz

120 ophobic small molecules to hydrophilic large biologics, can be efficiently loaded into biodegradable

121 F dual dAb, in comparison to other anti-VEGF biologics, can be explained by increased binding stoichi

122 ple chemotherapeutics, chemotherapeutics and biologics, chemotherapeutics and photodynamic therapy, a

123 ecrosis factor (anti-TNF) therapies or other biologics commonly used to treat immune-mediated disease

124 ional Comprehensive Cancer Network Drugs and Biologics Compendium, DRUGDEX, and Clinical Pharmacology

125 Other biologics considered potentially efficacious are still u

126 ced technologies into the development of new biologics could greatly reduce time and costs required t

127 Chemistry-derived access to homogeneous biologics could well have useful consequences in the dis

128 nt of allergic and respiratory disorders and biologics currently in development or recently abandoned

129 ogel using the NOGA-guided MyoStar catheter (Biologics Delivery Systems, Irwindale, California), and

130 Methotrexate and biologics did not affect humoral responses, but low pati

131 ng so far, although preliminary studies with biologics directed at adhesion molecules are encouraging

132 with type 2 inflammation, repeated trials of biologics directed toward type 2 cytokine pathways saw n

133 Administration of TNF-neutralizing biologics disrupted the control of mycobacterial infecti

134 eliver chemical drugs without excipients and biologics drugs in the presence of sugar excipients into

135 orona, and the ability to easily encapsulate biologics during particle preparation using a mild solve

136 re seen in the comparisons between the newer biologics (e.g. vedolizumab) and the anti-tumor necrosis

137 Small molecules and biologics (e.g., proteins and antibodies) with high affi

138 ost and parenteral mode of administration of biologics, efforts to develop oral small molecule inhibi

139 od safety profiles, immunomodulatory agents, biologics (eg monoclonal antibodies), nutritional produc

140 1) Biologics (enamel matrix derivative and recombinant huma

141 We show that multivalent biologics, engineered using carbohydrate-binding modules

142 The success of early biologics, especially etanercept and infliximab for the

143 mmunogenicity was performed using Center for Biologics Evaluation and Research acceptability criteria

144 formulation continued to meet all Center for Biologics Evaluation and Research and Committee for Medi

145 Bacterial Polysaccharides in the Center for Biologics Evaluation and Research and transferred to the

146 In the United States, the Center for Biologics Evaluation and Research of the US Food and Dru

147 of antigen and adjuvant dose; the Center for Biologics Evaluation Research and Review (CBER) licensur

148 The survival rates of the first course of biologics for 3,523 biologic-naive patients with chronic

149 ADCs) are among the most promising empowered biologics for cancer treatment.

150 decisions for AMD, as well as lessons on how biologics for ocular disease should be implemented into

151 tumor necrosis factor (TNF) and non anti-TNF biologics for rheumatoid arthritis (RA) focused on compa

152 ergy, with an emphasis on future targets for biologics for the treatment of food allergy.

153 dies provided outcome analysis on the use of biologics for the treatment of intrabony defects.

154 e, evaluated the effectiveness of the use of biologics for the treatment of intrabony defects.

155 decade has seen the approval of several new biologics for the treatment of severe asthma-targeting s

156 phritis and urge the consideration of proper biologics for the treatment of the disease.

157 ell 17 pathway-the target of next-generation biologics for treating psoriasis-based on clinical pheno

158 m for rapid and switchable production of two biologics from a single yeast strain as specified by the

159 The development of biologics has greatly increased the quality of life and

160 Pharmacologics and biologics have been used in combination with calcium pho

161 hin the field of uveitis, systemic and local biologics have been used to effectively treat uveitis, t

162 As biologics have improved the prognosis for rheumatoid art

163 Recent efficacy studies of asthma biologics have included highly enriched patient populati

164 ifferences between anti-TNF and non anti-TNF biologics have shown little differences among these.

165 oclonal antibodies and peptides, among other biologics, have been encapsulated in silk using various

166 , more specific drugs, collectively known as biologics, have been used in the treatment of uveitis.

167 number of emerging treatments, predominantly biologics, have shown substantial efficacy and reasonabl

168 ork was to assess the safety and efficacy of biologics (ie, tumor necrosis factor-alpha antagonists a

169 he relatively recent development of numerous biologics, immunogenicity testing has become a key compo

170 variety of novel therapies including the new biologics, immunosuppressives, and stem cell transplanta

171 ble and near-single-dose production of these biologics in <24 h with limited infrastructure requireme

172 The clinical success of TNFalpha blocking biologics in a growing number of immune-mediated patholo

173 as platforms for presenting receptor-binding biologics in a multivalent format that facilitates recep

174 The successes and failures of biologics in clinical trials have facilitated our abilit

175 eceptor antagonist, but the utility of other biologics in MAS is not clear.

176 thod that has been adopted for encapsulating biologics in nanoparticles (40-200nm) at high loadings (

177 o be done before advocating the use of these biologics in other settings.

178 up) and studies of treatment response in the Biologics in Rheumatoid Arthritis Genetics and Genomics

179 Dry preservation of biologics in sugar glasses is regarded as a promising al

180 iggered release of various nanoparticles and biologics in the presence of physiological levels of enz

181 es for the introduction of IL-17-suppressing biologics in the treatment of patients with systemic lup

182 supported by the effectiveness of anti-IL-1 biologics in treatment of these disorders.

183 hift away from devices and drugs, and toward biologics, in the treatment of rhythm disorders.

184 tistically significantly more frequent among biologics (incidence rate ratio [IRR] = 1.93; 95% CI, 1.

185 These biologics include immunotherapy with novel anti-IgE anti

186 he nested case-control studies, therapy with biologics increased the risk of melanoma (odds ratio [OR

187 ase who were scheduled to begin therapy with biologics (infliximab or adalimumab) were included, with

188 otential to induce ADAs after treatment with biologics is a safety issue that has become an important

189 d order for combining a second modality with biologics is biologic and methotrexate combination, biol

190 of TMP-SMZ prophylaxis in patients receiving biologics is necessary to prove that its utility outweig

191 y modified bacteria as delivery vehicles for biologics is of considerable interest scientifically and

192 In the era of biologics, laboratory tests have become essential to eva

193 ical data that supported the approval of the Biologics License Application (BLA) for belatacept for p

194 Biologics like anti-TNF, anti-interleukin-6 (IL-6), anti

195 otein-based pharmacokinetic approaches using biologics like vaccines, monoclonal antibodies, and enzy

196 X as the only biologic vs those unexposed to biologics (malignancy: 1.12/1000 patient-years; HLH: 0.5

197 mice with lupus and that p60 PLAD or similar biologics may be of clinical value if applied locally.

198 r treatments, including the recently popular biologics, may be effective in the control of chronic uv

199 ons, such as long-acting bronchodilators and biologics, may be required in moderate and severe asthma

200 maceuticals, including inhaled therapies and biologics, might be key to their treatment.

201 her protective nor deleterious effects (with biologics monotherapy, odds ratio [OR] 1.0, 95% CI 0.5-1

202 ith the use of newer medications, especially biologics, mostly directed towards immune system manipul

203 flammatory drugs (NSAIDs) (n = 8), and IR to biologics (n = 3).

204 Biologics-naive RA patients under the care of a rheumato

205 will be helpful for the testing of specific biologics neutralizing human TNF.

206 t safety events of novel pharmaceuticals and biologics occur when new safety risks are identified aft

207 PEGylation of biologics offers enhanced stability, duration, and reduc

208 ferent immunosuppressive regimens, including biologics, on HBV reactivation (HBVr) among patients wit

209 e include administration of small molecules, biologics or biomaterials that target specific aspects o

210 bers have been restricted to the delivery of biologics or hydrophobic small molecules at low drug loa

211 This finding might aid the design of novel biologics or probiotics to treat inflammatory bowel dise

212 sts were higher in IBD patients treated with biologics (OR = 3.98, CI: 3.72-4.27, p < 0.001) when com

213 ase (P = .046) and undergoing treatment with biologics (P = .04).

214 d fewer immunosuppressants drugs used before biologics (P=0.054) in responders (ie, complete or parti

215 nstays of treatment are immunomodulators and biologics, particularly anti-tumor necrosis factor.

216 ide reasonable guidelines for the use of the biologics, perhaps the best we can do is to extrapolate

217 y, odds ratio [OR] 1.0, 95% CI 0.5-1.9; with biologics plus MTX combination therapy, OR 0.8, 95% CI 0

218 on therapy, OR 0.8, 95% CI 0.3-2.0; and with biologics plus other immunosuppressive agents, OR 1.2, 9

219 in therapeutics and gradually increasing the biologics portion of their pipelines.

220 With the passage of the Biologics Price Competition and Innovation Act of 2009,

221 C) as a PAT tool for monitoring a continuous biologics process and forced degradation studies.

222 Biologics, psychiatric therapeutics, and accelerated and

223 idic device for the continuous monitoring of biologics' purity and bioactivity with high sensitivity,

224 novel prototype nanostructures consisting of biologics, radionuclides, fluorochromes, and CNT could b

225 le differences between innovator and copycat biologics raise questions regarding product interchangea

226 ta from the British Society for Rheumatology Biologics Register, a national prospective observational

227 ited to the British Society for Rheumatology Biologics Register.

228 RA from the British Society for Rheumatology Biologics Register.

229 idemiologic tools to studies of TB in future biologics registries.

230 disease-modifying antirheumatic drugs and/or biologics remain controversial, as does the role of stat

231 ional modulation of the immune response with biologics represents one of the most promising and activ

232 g after Rotarix vaccination (GlaxoSmithKline Biologics, Research Triangle Park, North Carolina) colle

233 Search terms included "biologics", "rheumatoid arthritis" and their synonyms.

234 Other biologics similarly inhibit TH2 cytokines (thymic stroma

235 le and demand-based production of functional biologics starting from DNA sequence information.

236 Biologics such as etanercept are the most successful dru

237 modulators such as mycophenolate mofetil and biologics such as rituximab are effective in halting dis

238 A number of medications, including biologics such as tumor necrosis factor alpha and interf

239 Combining biologics, such as etanercept or adalimumab, with photot

240 impurities in recombinantly produced protein biologics, such as host cell proteins (HCP), can potenti

241 The clinical application of biologics supports improvements in clinical parameters c

242 mune diseases, particularly psoriasis, where biologics targeting IL-23 and IL-17 have shown significa

243 Biologics targeting vascular endothelial growth factor (

244 (LIS) had 70% lower odds of having received biologics than those with LIS (odds ratio 0.30; 95% conf

245 ydrocarbon staples, are an emerging class of biologics that are capable of disrupting protein-protein

246 Enhancement Agents (VEAs) are a new class of biologics that are designed to increase the uptake of ca

247 e useful for understanding the mechanisms of biologics that are used in patients.

248 ts toward development of small molecules and biologics that could be of therapeutic use.

249 Cyclotides are a new class of plant biologics that display a diverse range of bioactivities

250 ven models and compared with other anti-VEGF biologics that have been used in ocular anti-angiogenic

251 Treg biology so as to develop pharmacologics/biologics that modulate Treg for asthma therapy.

252 Biologics that neutralize specific cytokines have improv

253 ng to be effective in humans, as many of the biologics that provide significant benefit in preclinica

254 The development of targeted biologics that recognize tumor cell surface antigens and

255 nhibitors of TNF (DN-TNFs) as a new class of biologics that selectively inhibits solTNF.

256 isease is improved by treatment with current biologics that target disease-specific pathways is uncle

257 he advent of systemic immunosuppressives and biologics, the use of corticosteroids remains in the man

258 </=90 kg or >90 kg) and previous exposure to biologics therapy for psoriasis.

259 Among patients taking biologics, these treatments were discontinued at 5 times

260 ring, and the real-time quality assurance of biologics throughout the biomanufacturing processes.

261 that it is possible to discriminate between biologics to inform clinical practice and decision makin

262 (AF) repair strategy that delivers cells and biologics to IVD injury site is needed to limit the prog

263 re biomarkers that enhance the usefulness of biologics to manage uncontrolled asthma, urticaria, and

264 gs, the time and costs required to bring new biologics to market still are substantial.

265 e stimulants and immune checkpoint inhibitor biologics to produce durable cures in mouse models of gl

266 apies, leading to the development of several biologics to treat allergic diseases.

267 bination chemotherapy regimens plus or minus biologics, to render initially unresectable metastases r

268 he US Food and Drug Administration regulates biologics used for diagnosis and treatment of allergic d

269 assessed the risk of serious infections for biologics used to treat psoriasis by comparison with a c

270 We assessed the drug survival of biologics used to treat psoriasis in a prospective natio

271 fluorescent labeling of target proteins and biologics using click chemistries, (ii) for glycoenginee

272 btle differences in vibrational modes of the biologics, we have developed partial least-squares-discr

273 With the renewed interest in anti-TH2 biologics, we propose a rationale for why they are parti

274 Similarly, the odds of having received biologics were 69% lower among black patients compared w

275 Biologics were associated with an increased risk of nonm

276 A number of different drugs or biologics were critically reviewed and 3 different poste

277 the total costs in IBD patients treated with biologics were due to drug costs, compared with 28% in p

278 All included biologics were efficacious compared with placebo or meth

279 The biologics were supplemented with an initial 1-month trea

280 tory approval for the marketing of drugs and biologics when only a single pivotal phase 3 clinical tr

281 Protein-based biologics, which leverage the inherent affinity and spec

282 Biologics, which target specific cytokines and pathways,

283 TNFi and other biologics whose constructs contain a functional IgGFc pi

284 rm safety is demonstrated, it is likely that biologics will be introduced as therapy earlier in the c

285 e are overall insufficient data on combining biologics with acitretin, cyclosporine, or a second biol

286 ication in the delivery of novel therapeutic biologics with enhanced functional properties for the tr

287 ntify direct and indirect evidence comparing biologics with one another, methotrexate, or placebo.

288 reports of infections in patients receiving biologics with organisms such as Pneumocystis, Listeria,

289 18, 2013, that evaluated therapies combining biologics with phototherapy, oral medications, or other

290 tial strategy of etanercept-methotrexate and biologics with similar cost and efficacy is unlikely to

291 Bispecific biologics with such dual functions may therefore represe

292 ic alpha-helix mimetics, proteomimetics, and biologics with the therapeutic potentials of inhibiting

293 es that combine the advantageous features of biologics with those of small-molecule drugs.

294 c scaffolds are more appropriate for smaller biologics without secondary structure.